CurveBeam AI (ASX:CVB) Earnings Yield (Joel Greenblatt) %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CurveBeam AI Earnings Yield (Joel Greenblatt) %?

CurveBeam AI ASX:CVB Earnings Yield (Joel Greenblatt) % is 0.00% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 849 Medical Devices & Instruments companies, CurveBeam AI ranks worse than 91.28% on this metric.

CurveBeam AI's Enterprise Value for the quarter that ended in Dec. 2025 was A$48.49 Mil. CurveBeam AI's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-15.41 Mil. CurveBeam AI's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for CurveBeam AI's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

ASX:CVB' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -239.97   Med: -50.64   Max: -21.11
Current: -70.42

During the past 5 years, the highest Earnings Yield (Joel Greenblatt) of CurveBeam AI was -21.11%. The lowest was -239.97%. And the median was -50.64%.

ASX:CVB's Earnings Yield (Joel Greenblatt) % is ranked worse than
91.28% of 849 companies
in the Medical Devices & Instruments industry
Industry Median: 0.89 vs ASX:CVB: -70.42

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. CurveBeam AI's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


CurveBeam AI  (ASX:CVB) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


CurveBeam AI Earnings Yield (Joel Greenblatt) % Related Terms


CurveBeam AI Earnings Yield (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for CurveBeam AI's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CurveBeam AI Earnings Yield (Joel Greenblatt) % Chart

CurveBeam AI Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Earnings Yield (Joel Greenblatt) %
0.00 0.00 0.00 -35.59 -37.88

CurveBeam AI Semi-Annual Data
Jun21 Dec21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only 0.00 -35.59 0.00 -37.88 0.00

ASX:CVB vs ABT, SYK, MDT: Earnings Yield (Joel Greenblatt) % Comparison

For the Medical Devices subindustry, CurveBeam AI's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CurveBeam AI Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CurveBeam AI's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where CurveBeam AI's Earnings Yield (Joel Greenblatt) % falls into.



CurveBeam AI Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

CurveBeam AIs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2025 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-16.152/42.639147
=-37.88 %

For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.


What does a Earnings Yield (Joel Greenblatt) % of 0.00% mean?
CurveBeam AI (ASX:CVB) has a Earnings Yield (Joel Greenblatt) % of 0.00% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on CurveBeam AI and its competitors. According to the industry distribution chart, CurveBeam AI ranks #775 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 91.3%.
Is CurveBeam AI's Earnings Yield (Joel Greenblatt) % too high?
CurveBeam AI's current Earnings Yield (Joel Greenblatt) % is 0.00%. Based on the distribution chart, CurveBeam AI ranks #775 out of 849 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does CurveBeam AI's Earnings Yield (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CurveBeam AI ranks #775 out of 849 companies for Earnings Yield (Joel Greenblatt) %. This places CurveBeam AI in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.89, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on CurveBeam AI and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CurveBeam AI's current Earnings Yield (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
CurveBeam AI (ASX:CVB) has a current Earnings Yield (Joel Greenblatt) % of 0.00%. The current Earnings Yield (Joel Greenblatt) % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current Earnings Yield (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CurveBeam AI Business Description

Address 10 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.